ABSTRACT Plasmid-encoded colistin resistance is emerging among extraintestinal pathogenic Escherichia coli strains, including those of the epidemic clone sequence type 131 (ST131)-H30. Mcr-1 transfers a phosphoethanolamine to the lipid A portion of lipopolysaccharide (LPS), conferring resistance to polymyxins. We investigated whether this modification changed the activity of the monoclonal antibody ASN-4, specific to the O25b side chain of ST131 LPS. We confirmed that, unlike colistin, ASN-4 retained its bactericidal and endotoxin-neutralizing activities and therefore offers a treatment option against extremely drug-resistant ST131 isolates.
C
olistin (polymyxin E) and polymyxin B are considered to be last-resort antibiotics against multidrug-resistant (MDR) Gram-negative bacteria. With the spread of carbapenem-resistant pathogens, the use of colistin has increased, leading to the emergence of colistin resistance (1) . Recent reports on the plasmid-mediated colistin resistance determinants, mcr-1 and allelic variants thereof (2) (3) (4) , underline the importance of transmissible resistance genes in the rapid emergence of colistin resistance (1) . The acquisition of mcr-1 by isolates belonging to globally spread MDR high-risk clonal lineages, including Escherichia coli clone sequence type 131 (ST131)-H30, poses a major threat to the health care system.
The gene product of the mcr alleles transfers a phosphoethanolamine residue to the lipid A moiety of the lipopolysaccharide (LPS) (4), i.e., the molecular target of polymyxins. The modified lipid A has much lower affinity for colistin and related polymyxins, resulting in reduced activities for these drugs. Beyond conferring resistance to polymyxins, Mcr-1 was also shown to alter the susceptibility of bacteria to antimicrobial peptides (5) and unrelated antibiotics (6). Additionally, a high level of Mcr-1 expression was reported to compromise growth rate, fitness, and outer membrane structural integrity through the integration of Mcr-1 into the membrane, as well as its enzymatic activity, i.e., the modification of the lipid A (6).
We have previously reported humanized monoclonal antibodies (7) targeting the lipopolysaccharide O25b antigen associated with the ST131-H30 clone (8) , the most prevalent extraintestinal pathogenic E. coli (ExPEC) lineage, responsible for a wide range of infections. We demonstrated that these monoclonal antibodies (MAbs) have complementdependent bactericidal, opsonophagocytic, and endotoxin-neutralizing activities that contribute to protection in murine models (9) .
In the current study, we show that all three mechanisms of action of an O25b-specific MAb, ASN-4, were retained against E. coli ST131-H30 isolates producing Mcr-1. ASN-4 shares the complementarity-determining region (CDR) sequences of the previ-ously published MAb A1124 (9) and therefore has identical binding specificity and affinity (with only two amino acid changes in the framework region).
To compare the potency of ASN-4 against Mcr-1-producing versus -nonproducing strains, an isogenic ST131-H30 pair was generated. The open reading frame of mcr-1 was cloned from the bloodstream isolate ABC149 (10) into the SalI and EcoRI sites of plasmid pBAD322C (pBAD::mcr-1). Strain 81009 was transformed with pBAD::mcr-1 (VSZ197) or with the empty vector (VSZ198). The expression of mcr-1 was induced with 0.02% arabinose, which resulted in a 4-fold elevation in the colistin MIC in VSZ197 compared to VSZ198.
The complement-dependent bactericidal and opsonophagocytic activities of ASN-4 were measured as described previously (9) . In 50% human serum as a complement source, ASN-4 mediated significant killing of both strains (Fig. 1A) . Similarly, in the presence of active complement, ASN-4 significantly increased the uptake of either strain by murine macrophages (compared to a control IgG) (Fig. 1B) . No significant difference was observed between the activities against mcr-1-expressing and -nonexpressing strains in any of these assays. These data confirm that the expression of mcr-1 did not influence the binding of ASN-4 to the LPS O antigen or the integration of the complement membrane-attackcomplex (MAC) into the structurally altered outer membrane.
The proinflammatory activity of the LPS is primarily mediated by its lipid A portion (i.e., the endotoxin). Although ASN-4 does not directly target the lipid A moiety, but rather the carbohydrate part of LPS, we were able to show that A1124, the parent MAb, neutralized the proinflammatory activity of LPS both in vitro and in vivo (9) . This activity can originate from steric blocking of the lipid A binding to its receptor complex or from the stabilization of the supramolecular micelle structure of LPS that may be affected by the mcr-1-encoded modification. Therefore, it was of particular interest to evaluate Data shown in panels A to C are presented as the mean Ϯ standard error of the mean (SEM), and groups were compared with Student t test, while on panel D, Mantel-Cox survival curves were analyzed with the log-rank test. *, P Ͻ 0.05; ***, P Ͻ 0.001. In all experiments, an isotype-matched (human IgG1) MAb with irrelevant specificity was used as a negative control. NHS, normal human serum; HI, heat inactivated.
whether the neutralizing activity of ASN-4 against LPS altered by Mcr-1 would be affected. The reporter cell line HEK-Blue hTLR4 (InvivoGen) was used to measure endotoxin-induced Toll-like receptor 4 (TLR-4) signaling. Cells were incubated with purified LPS extracted from VSZ197, VSZ198, or the mcr-1-expressing clinical ST131-H30 isolate, ABC149, in the presence of ASN-4 or the endotoxin-neutralizing antibiotic, colistin. The signal triggered by the different LPS samples alone was adjusted to be comparable. Next, we determined the MAb or colistin concentration required for 50% reduction (50% effective concentration [EC 50 ]) of the TLR-4 activation signal (Fig. 1C) . While the neutralizing potencies of colistin against strains VSZ197 and ABC149 were 12-and 27-fold lower, respectively, than that against the colistin-susceptible strain VSZ198, ASN-4 had comparable LPS-neutralizing capacity against all E. coli ST131 strains independent of the presence of mcr-1.
To further corroborate this finding, we tested the efficacy of ASN-4 in a mouse endotoxemia model. Animal experiments were reviewed and approved by Arsanis' Animal Welfare and Ethics Committee and were performed according to Austrian law (BGBl. I no. 114/2012, https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2012_I _114/BGBLA_2012_I_114.html), as approved by the respective competent authority (Magistratsabteilung 58, Vienna, Austria). Six-to eight-week-old female BALB/cJRj mice were sensitized to endotoxin (11) , passively immunized with different doses of ASN-4 or a control MAb, and 24 h later challenged with a lethal dose of purified LPS extracted from strain ABC149. Prophylactically administered ASN-4 provided significant protection at a dose of 6.25 g/animal (ϳ300 g/kg of body weight) or higher (Fig. 1D ). This efficacy is comparable to that observed previously against a colistin-susceptible clinical isolate (9) .
In conclusion, we demonstrate that all three mechanisms of action, i.e., complementmediated killing, opsonophagocytosis, and endotoxin neutralization, of the O25b-specific MAb ASN-4 have been retained against an mcr-1-positive colistin-resistant ST131-H30 strain. Consequently, the use of such LPS O-antigen-targeting antibodies can be considered an alternative strategy to combat MDR infections, even against the emerging mcr-1-positive isolates.
